Drug discovery today. Disease mechanisms最新文献_第3页

A new horizon: oxytocin as a novel therapeutic option for obesity and diabetes 一个新的视野:催产素作为肥胖和糖尿病的一种新的治疗选择

Drug discovery today. Disease mechanisms Pub Date : 2013-06-01 DOI: 10.1016/j.ddmec.2013.05.006

Dongsheng Cai, Sudarshana Purkayastha

{"title":"A new horizon: oxytocin as a novel therapeutic option for obesity and diabetes","authors":"Dongsheng Cai, Sudarshana Purkayastha","doi":"10.1016/j.ddmec.2013.05.006","DOIUrl":"10.1016/j.ddmec.2013.05.006","url":null,"abstract":"<div>The story of oxytocin (OXT) began long ago in evolutionary terms with its recognition as a classical neurohypophyseal hormone important for lactation and uterine contraction. With the recent discovery of its local actions in the brain, its previously unappreciated diverse functions in regulating social behaviors and metabolic physiology are emerging. In light of metabolic control, OXT has been shown to induce feeding restriction and body weight lowering through acting on brain regulatory regions, in particular the hypothalamus. Studies from pharmacologic interventions and genetic manipulations demonstrated that OXT can play significant roles in affecting glucose metabolism as well as insulin secretion and lipolysis, many of those functions being regulated both centrally and peripherally. Also excitingly, recent therapeutic success was obtained in clinical endeavor showing that OXT nasal spray effectively induced weight loss and metabolic improvement in human patients with obesity, thus further indicating OXT as a tangible drug target for treating obesity and metabolic complications. In addition to the native form, OXT-derived analogues have been found effective in inducing body weight control and glucose balance. Altogether, all recent advances in the understanding of OXT and metabolic regulation has laid a promising foundation for the therapeutic strategy of developing innovative OXT peptidyl drugs for the treatment of obesity and related metabolic diseases</div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"10 1","pages":"Pages e63-e68"},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2013.05.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40266696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35

Obesity and obesity-induced disorders: from molecular mechanisms to promising therapeutic targets 肥胖和肥胖引起的疾病:从分子机制到有希望的治疗靶点

Drug discovery today. Disease mechanisms Pub Date : 2013-06-01 DOI: 10.1016/j.ddmec.2013.06.001

Haiming Cao

引用次数: 1

An update on the regulation of adipogenesis 脂肪形成调控的最新进展

Drug discovery today. Disease mechanisms Pub Date : 2013-06-01 DOI: 10.1016/j.ddmec.2013.04.002

Miao-Hsueh Chen, Qiang Tong

引用次数: 8

Obesity, cancer and acetyl-CoA metabolism 肥胖，癌症和乙酰辅酶a代谢

Drug discovery today. Disease mechanisms Pub Date : 2013-06-01 DOI: 10.1016/j.ddmec.2013.03.005

Joyce V. Lee, Supriya A. Shah, Kathryn E. Wellen

引用次数: 25

Sirtuin 3: a major control point for obesity-related metabolic diseases? Sirtuin 3:肥胖相关代谢疾病的主要控制点?

Drug discovery today. Disease mechanisms Pub Date : 2013-06-01 DOI: 10.1016/j.ddmec.2013.04.001

Sean A. Newsom , Kristen E. Boyle , Jacob E. Friedman

引用次数: 15

The genetic influence on body fat distribution 基因对身体脂肪分布的影响

Drug discovery today. Disease mechanisms Pub Date : 2013-06-01 DOI: 10.1016/j.ddmec.2013.05.003

Robert Wagner , Fausto Machicao , Andreas Fritsche , Norbert Stefan , Hans-Ulrich Häring , Harald Staiger

{"title":"The genetic influence on body fat distribution","authors":"Robert Wagner , Fausto Machicao , Andreas Fritsche , Norbert Stefan , Hans-Ulrich Häring , Harald Staiger","doi":"10.1016/j.ddmec.2013.05.003","DOIUrl":"10.1016/j.ddmec.2013.05.003","url":null,"abstract":"<div>Measures of general adiposity have limitations in the prediction of metabolic complications of obesity. Body fat compartments, such as abdominal visceral fat, interscapular fat, perivascular fat around the brachial artery, perivascular fat around the thoracic artery and liver fat content, correlate better with insulin resistance, glucose intolerance, diabetes and hypertension than body mass index. Finding the origin of specific fat compartments could help in the development of new therapeutic strategies.The profound genetic determination of body fat distribution has been demonstrated in twin studies and complex segregation analyses. Genome-wide association studies delivered clear evidence for an association of specific genes or genetic regions with waist-to-hip ratio, waist circumference, visceral fat area, and pericardial fat determined by computed tomography. Many of these SNPs and genes also associate with metabolic end-points, such as insulin resistance and diabetes. Candidate gene studies also discovered polymorphisms that are suggested to be associated with markers of body fat distribution. Although most of the results of small studies are not replicated, the problem with hypothesis-free approaches is the low effect size of discovered variants and, in most cases, the lack of pathomechanistic explanations. Further studies using more sophisticated methods for the assessment of body fat distribution are needed to advance our knowledge in this field.</div>","PeriodicalId":72843,"journal":{"name":"Drug discovery today. Disease mechanisms","volume":"10 1","pages":"Pages e5-e13"},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmec.2013.05.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80835242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Mechanisms of airway remodeling in asthma 哮喘气道重塑的机制

Drug discovery today. Disease mechanisms Pub Date : 2012-12-01 DOI: 10.1016/j.ddmec.2012.11.004

James G. Martin, Neil Verma

引用次数: 6

Inflammatory phenotypes in asthma pathogenesis 哮喘发病机制中的炎症表型

Drug discovery today. Disease mechanisms Pub Date : 2012-12-01 DOI: 10.1016/j.ddmec.2012.09.001

Russell S. Traister , Sally E. Wenzel

引用次数: 8

Airway epithelial–mesenchymal interactions in the pathogenesis of asthma 哮喘发病机制中的气道上皮-间质相互作用

Drug discovery today. Disease mechanisms Pub Date : 2012-12-01 DOI: 10.1016/j.ddmec.2012.09.002

Stephen T. Holgate

引用次数: 0

TSLP: a key regulator of asthma pathogenesis TSLP:哮喘发病机制的关键调节因子

Drug discovery today. Disease mechanisms Pub Date : 2012-12-01 DOI: 10.1016/j.ddmec.2012.09.003

Erin E. West, Mohit Kashyap, Warren J. Leonard

引用次数: 62